Iovance Biotherapeutics Inc (IOVA)
Drugs • Health Care
Percentage
Change
| Mar 12 | Sep 13 | Mar 14 | Mar 15 | Mar 16 | Mar 17 | Mar 18 | Feb 19 | Feb 20 | Feb 21 | Feb 22 | Feb 23 | Feb 24 | Feb 25 | Feb 26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income to Common | -372 | -391 | |||||||||||||
Net Income | -372 | -391 | |||||||||||||
Profit | -372 | -391 | |||||||||||||
Net Income Continuing | -372 | -391 | |||||||||||||
Income Tax Expense | 3 | 2 | |||||||||||||
Pretax Income | -375 | -393 | |||||||||||||
Total Non-operating Income | 20 | 10 | |||||||||||||
Operating Income | -395 | -403 | |||||||||||||
Total Revenue | 164 | 264 | |||||||||||||
Total Costs and Expenses | -559 | -667 | |||||||||||||
Cost of Revenue | -124 | -173 | |||||||||||||
Operating Expenses | -435 | -494 | |||||||||||||
Depreciation, Depletion & Amortization Expense | 0 | -36 | |||||||||||||
Research and Development Expenses | -282 | -300 | |||||||||||||
Restructuring Charge | 0 | -5 | |||||||||||||
Selling, General & Administrative Expenses | -153 | -152 | |||||||||||||
Other Operating Expenses | 0 | -0 |